{"news_desk": "SundayBusiness", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By GRETCHEN MORGENSON", "person": [{"firstname": "Gretchen", "rank": 1, "lastname": "MORGENSON", "organization": "", "role": "reported"}]}, "abstract": "Gretchen Morgenson Fair Game column describes how executives at pharmaceutical giant Mylan stand to profit from excessive pricing of its EpiPen allergy treatment; observes connection between treatment's unusual price rise and company's announcement of one-time stock grant that will lavishly reward executives if earnings and stock price meet certain goals by end of 2018; notes irregularities in Mylan's account of its earnings.", "type_of_material": "News", "word_count": "1199", "keywords": [{"rank": "1", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Bresch, Heather", "is_major": "N", "name": "persons"}, {"rank": "3", "value": "Mylan Inc", "is_major": "Y", "name": "organizations"}, {"rank": "4", "value": "Executive Compensation", "is_major": "Y", "name": "subject"}, {"rank": "5", "value": "Abbott Laboratories", "is_major": "N", "name": "organizations"}, {"rank": "7", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "8", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}, {"rank": "9", "value": "Allergies", "is_major": "Y", "name": "subject"}], "lead_paragraph": "Filings show that under a one-time stock grant created in 2014, top executives stand to reap riches at least partly on the back of price increases on the EpiPen.", "pub_date": "2016-09-01T17:38:46+0000", "document_type": "article", "source": "The New York Times", "snippet": "Filings show that under a one-time stock grant created in 2014, top executives stand to reap riches at least partly on the back of price increases on the EpiPen....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/02/business/02GRET/02GRET-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/02/business/02GRET/02GRET-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/09/02/business/02GRET/02GRET-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/02/business/02GRET/02GRET-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/02/business/02GRET/02GRET-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/02/business/02GRET/02GRET-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/04/business/at-mylan-lets-pretend-is-more-than-a-game.html", "slideshow_credits": null, "blog": [], "_id": "57c867ac95d0e021d7983dd3", "headline": {"main": "EpiPen Price Rises Could Mean More Riches for Mylan Executives", "content_kicker": "Fair Game", "print_headline": "EpiPen Soars and So Does Bosses\u2019 Pay", "kicker": "Fair Game"}}